The phase 2 study demonstrated that verekitug successfully lowered the annualized asthma exacerbation rate across all tested dose regimens. Notably, a 100-milligram dose administered every 12 weeks achieved a 56% reduction in exacerbations compared to a placebo. Beyond frequency, the drug showed measurable improvements in lung function and exhaled nitric oxide levels.
In section Market Quotes
Upstream Bio Shares Rally After Positive Asthma Drug Trial
A 9.3% jump in premarket trading on Tuesday signals renewed investor confidence in Upstream Bio, as the company’s experimental asthma treatment, verekitug, hit primary endpoints in a mid-stage clinical trial. The stock’s climb offers a rare reprieve following a 78% decline throughout the current calendar year.
Aaron Deykin, the company's chief medical officer, highlighted the results as validation of the drug's potential for best-in-class efficacy paired with the convenience of quarterly administration. Upstream Bio intends to carry this momentum into larger phase 3 trials, with preparations currently underway for a broader patient population. The company confirmed it remains on schedule to launch those late-stage studies for severe asthma and chronic rhinosinusitis with nasal polyps in the first quarter of 2027.
Comments (0)
No comments yet. Be the first!